Đang chuẩn bị liên kết để tải về tài liệu:
Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: A comparative study

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Central nervous system (CNS) brain metastasis of advanced non-small cell lung cancer (NSCLC) patients confers a worse quality of life and prognosis. The efficacy comparison of two first-generation epidermal growth factor receptor (EGFR) inhibitors erlotinib or gefitinib as first-line treatment for CNS metastasis NSCLC patients with EGFR-sensitizing mutations is yet to be elucidated. |

TÀI LIỆU LIÊN QUAN

Ebook Escourolle & poirier’s manual of basic neuropathology: Part 1

Ebook The central nervous system - Structure and function (4/E): Part 1

Educational case: Opportunistic infections of the central nervous system

Ebook King’s applied anatomy of the central nervous system of domestic mammals (2/E): Part 2

Increasing incidence of central nervous system (CNS) tumors (2000–2012): Findings from a population based registry in Gironde (France)

Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment

MYC and BCL2 overexpression is associated with a higher class of Memorial SloanKettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system

Ebook Pediatric critical care medicine (Volume 2: Respiratory, cardiovascular and central nervous systems - 2nd edition): Part 2

Neuroscience and review of illustrated: Part 1

Ebook Imaging of non-traumatic ischemic and hemorrhagic disorders of the central nervous system